The Retention of 14C-DTPA in Human Volunteers After Inhalation Or Intravenous Injection

Abstract

This study in human volunteers was designed to compare the retention of diethylenetriaminepentaacetic acid (DTPA) in the body after intravenous (i.v.) injection with that following inhalation by using a 14C labelled tracer. After i.v. injection retention in the blood could be described by three exponential components with half-times of about 1.4 min (approximately 60%) 14.3 min (approximately 20%) and 95 min (approximately 20%). By 24 hr more than 99% of the 14C-DTPA had been excreted in the urine and less than 0.5% remained in the plasma. After inhalation of 14C-DTPA retention in the lungs could be represented by a single component with a half time of about 75 min. As a consequence the length of time that a therapeutically useful amount of DTPA is retained in the body is approximately twice that following intravenous injection.

Exposure to actinides: report on Ca-DTPA injections in CEA-AREVA centres

“…It is nearly completely excreted 12 hours after its administration (Gusev et al, 2001;REAC/TS, 2002). A study on two healthy volunteers evidenced that in 24 hours, 99% of the Ca-DTPA injected was excreted in the urines and that less than 0.5% remained in the plasma (Stather et al, 1983).…”

“…From human data (Stather et al, 1983), the modelling results in plasma transfer rates to extra cellular fluids (ECF) (K1) extracellular fluids and from ECF to plasma (K2). These are very short with respective biological periods of 2.5 and 6.3 minutes.…”

Comparative Evaluation of Disodium Edetate and Diethylenetriaminepentaacetic Acid as Iron Chelators to Prevent Metal -Catalyzed Destabilization of a Therapeutic Monoclonal Antibody

“…DTPA is hydrophilic and is unlikely to penetrate cells to any great extent 39 . Early pharmacokinetic studies in animals 40,41 and in humans 42 showed that DTPA is very poorly distributed into tissues and is rapidly eliminated from the body via urine excretion after either intravenous injection or inhalation.…”

Predicting Plutonium Decorporation Efficacy after Intravenous Administration of DTPA Formulations: Study of Pharmacokinetic–Pharmacodynamic Relationships in Rats

“…In spite of its ability to chelate Pu in body fluids, DTPA is hydrophilic and thus does not penetrate cells to any great extent (4). Besides, early pharmacokinetic studies in animals (5,6) and in humans (7) showed that DTPA is generally very poorly distributed to tissues and is rapidly eliminated from the body after inhalation or intravenous injection.…”